Loading…
Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer
Purpose: We investigated the potential of circulating, nucleosomal DNA for the early prediction of the efficacy of chemotherapy in patients with advanced lung cancer. Experimental Design: In serum of 212 patients with newly diagnosed non–small cell lung cancer (stages III and IV) undergoing chemothe...
Saved in:
Published in: | Clinical cancer research 2004-09, Vol.10 (18), p.5981-5987 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03 |
---|---|
cites | cdi_FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03 |
container_end_page | 5987 |
container_issue | 18 |
container_start_page | 5981 |
container_title | Clinical cancer research |
container_volume | 10 |
creator | HOLDENRIEDER, Stefan STIEBER, Petra VON PAWEL, Joachim RAITH, Hannelore NAGEL, Dorothea FELDMANN, Knut SEIDEL, Dietrich |
description | Purpose: We investigated the potential of circulating, nucleosomal DNA for the early prediction of the efficacy of chemotherapy in
patients with advanced lung cancer.
Experimental Design: In serum of 212 patients with newly diagnosed non–small cell lung cancer (stages III and IV) undergoing chemotherapy, nucleosomes
(ELISA, Roche) were measured at days 1, 3, 5, and 8 of the first cycle and before each new therapeutic cycle. Additionally,
carcinoembryonic antigen and cytokeratin 19 fragments (CYFRA 21–1; Elecsys, Roche) were determined before each cycle. The
therapeutic success was classified by computed tomography before start of the third cycle according to the World Health Organization
criteria.
Results: In univariate analysis, responders (patients with remission) showed significantly ( P < 0.05) lower values for the area under the curve of days 1 to 8 (AUC 1–8) of nucleosomes, the pretherapeutic baseline values
of cycle 2 (BV2) and cycle 3 (BV3) of nucleosomes, and higher decreases of the baseline values from cycle 1 to 2 (BV1–2) and
from cycle 1 to 3 (BV1–3) compared with nonresponders (patients with stable or progressive disease). Additionally, CYFRA 21–1
(BV1, BV2, BV3, BV1–2, BV1–3) and carcinoembryonic antigen (BV1–2) discriminated significantly between both groups.
In multivariate analysis including all parameters available until end of the first therapeutic cycle, nucleosomes (AUC 1–8),
CYFRA 21–1 (BV1), stage, and age were independent predictors of therapy response with nucleosomes (AUC 1–8) having the strongest
impact.
Conclusion: Circulating nucleosomes in combination with oncological biomarkers are valuable for the early estimation of the efficacy
of chemotherapy in patients with lung cancer. |
doi_str_mv | 10.1158/1078-0432.CCR-04-0625 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66911684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66911684</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03</originalsourceid><addsrcrecordid>eNpFkUtu1TAUQC0EoqWwBJAnIDFIuY4_cYZVxE96KlWBseU4N41REj_shKoz9sAOWQlO30Od2Ff2uR8fE_KSwTljUr9jUOkCBC_Pm-Y6BwWoUj4ip0zKquClko9z_J85Ic9S-gHABAPxlJwwKURVa3ZKUuOjW0e7-PmGXq5uxJDChIleRey8W-gyIL3GtA9zQroE2gw4hXwY7f6O-ple5VScl0Rv_TLQi-6XnR129DLMf3__-TrZcaQN5mW35gbNdhmfkye9HRO-OO5n5PuH99-aT8Xuy8fPzcWucFzVS1H2JVc9b8sKpOt62WKnKiE0MMVF1yKAtNhxhSVUNVpgvVathF7X2pXWAj8jbw519zH8XDEtZvLJ5WHsjGFNRqmaMaVFBuUBdDGkFLE3--gnG-8MA7PZNptJs5k02XYOzGY75706NljbCbuHrKPeDLw-AjY5O_Yxv9-nB07lD9HAM_f2wA3-Zrj1EY27NxUxoY1uuJ9DG7nV_Ac3Epfj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66911684</pqid></control><display><type>article</type><title>Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer</title><source>Freely Accessible Journals</source><creator>HOLDENRIEDER, Stefan ; STIEBER, Petra ; VON PAWEL, Joachim ; RAITH, Hannelore ; NAGEL, Dorothea ; FELDMANN, Knut ; SEIDEL, Dietrich</creator><creatorcontrib>HOLDENRIEDER, Stefan ; STIEBER, Petra ; VON PAWEL, Joachim ; RAITH, Hannelore ; NAGEL, Dorothea ; FELDMANN, Knut ; SEIDEL, Dietrich</creatorcontrib><description>Purpose: We investigated the potential of circulating, nucleosomal DNA for the early prediction of the efficacy of chemotherapy in
patients with advanced lung cancer.
Experimental Design: In serum of 212 patients with newly diagnosed non–small cell lung cancer (stages III and IV) undergoing chemotherapy, nucleosomes
(ELISA, Roche) were measured at days 1, 3, 5, and 8 of the first cycle and before each new therapeutic cycle. Additionally,
carcinoembryonic antigen and cytokeratin 19 fragments (CYFRA 21–1; Elecsys, Roche) were determined before each cycle. The
therapeutic success was classified by computed tomography before start of the third cycle according to the World Health Organization
criteria.
Results: In univariate analysis, responders (patients with remission) showed significantly ( P < 0.05) lower values for the area under the curve of days 1 to 8 (AUC 1–8) of nucleosomes, the pretherapeutic baseline values
of cycle 2 (BV2) and cycle 3 (BV3) of nucleosomes, and higher decreases of the baseline values from cycle 1 to 2 (BV1–2) and
from cycle 1 to 3 (BV1–3) compared with nonresponders (patients with stable or progressive disease). Additionally, CYFRA 21–1
(BV1, BV2, BV3, BV1–2, BV1–3) and carcinoembryonic antigen (BV1–2) discriminated significantly between both groups.
In multivariate analysis including all parameters available until end of the first therapeutic cycle, nucleosomes (AUC 1–8),
CYFRA 21–1 (BV1), stage, and age were independent predictors of therapy response with nucleosomes (AUC 1–8) having the strongest
impact.
Conclusion: Circulating nucleosomes in combination with oncological biomarkers are valuable for the early estimation of the efficacy
of chemotherapy in patients with lung cancer.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-04-0625</identifier><identifier>PMID: 15447981</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm - blood ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Carcinoembryonic Antigen - biosynthesis ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Drug Resistance, Neoplasm ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Keratin-19 ; Keratins - metabolism ; Kinetics ; Lung Neoplasms - blood ; Lung Neoplasms - drug therapy ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Nucleosomes - metabolism ; Pharmacology. Drug treatments ; Time Factors ; Treatment Outcome ; Tumors</subject><ispartof>Clinical cancer research, 2004-09, Vol.10 (18), p.5981-5987</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03</citedby><cites>FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16141803$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15447981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOLDENRIEDER, Stefan</creatorcontrib><creatorcontrib>STIEBER, Petra</creatorcontrib><creatorcontrib>VON PAWEL, Joachim</creatorcontrib><creatorcontrib>RAITH, Hannelore</creatorcontrib><creatorcontrib>NAGEL, Dorothea</creatorcontrib><creatorcontrib>FELDMANN, Knut</creatorcontrib><creatorcontrib>SEIDEL, Dietrich</creatorcontrib><title>Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: We investigated the potential of circulating, nucleosomal DNA for the early prediction of the efficacy of chemotherapy in
patients with advanced lung cancer.
Experimental Design: In serum of 212 patients with newly diagnosed non–small cell lung cancer (stages III and IV) undergoing chemotherapy, nucleosomes
(ELISA, Roche) were measured at days 1, 3, 5, and 8 of the first cycle and before each new therapeutic cycle. Additionally,
carcinoembryonic antigen and cytokeratin 19 fragments (CYFRA 21–1; Elecsys, Roche) were determined before each cycle. The
therapeutic success was classified by computed tomography before start of the third cycle according to the World Health Organization
criteria.
Results: In univariate analysis, responders (patients with remission) showed significantly ( P < 0.05) lower values for the area under the curve of days 1 to 8 (AUC 1–8) of nucleosomes, the pretherapeutic baseline values
of cycle 2 (BV2) and cycle 3 (BV3) of nucleosomes, and higher decreases of the baseline values from cycle 1 to 2 (BV1–2) and
from cycle 1 to 3 (BV1–3) compared with nonresponders (patients with stable or progressive disease). Additionally, CYFRA 21–1
(BV1, BV2, BV3, BV1–2, BV1–3) and carcinoembryonic antigen (BV1–2) discriminated significantly between both groups.
In multivariate analysis including all parameters available until end of the first therapeutic cycle, nucleosomes (AUC 1–8),
CYFRA 21–1 (BV1), stage, and age were independent predictors of therapy response with nucleosomes (AUC 1–8) having the strongest
impact.
Conclusion: Circulating nucleosomes in combination with oncological biomarkers are valuable for the early estimation of the efficacy
of chemotherapy in patients with lung cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Neoplasm - blood</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Carcinoembryonic Antigen - biosynthesis</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Drug Resistance, Neoplasm</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Humans</subject><subject>Keratin-19</subject><subject>Keratins - metabolism</subject><subject>Kinetics</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Nucleosomes - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpFkUtu1TAUQC0EoqWwBJAnIDFIuY4_cYZVxE96KlWBseU4N41REj_shKoz9sAOWQlO30Od2Ff2uR8fE_KSwTljUr9jUOkCBC_Pm-Y6BwWoUj4ip0zKquClko9z_J85Ic9S-gHABAPxlJwwKURVa3ZKUuOjW0e7-PmGXq5uxJDChIleRey8W-gyIL3GtA9zQroE2gw4hXwY7f6O-ple5VScl0Rv_TLQi-6XnR129DLMf3__-TrZcaQN5mW35gbNdhmfkye9HRO-OO5n5PuH99-aT8Xuy8fPzcWucFzVS1H2JVc9b8sKpOt62WKnKiE0MMVF1yKAtNhxhSVUNVpgvVathF7X2pXWAj8jbw519zH8XDEtZvLJ5WHsjGFNRqmaMaVFBuUBdDGkFLE3--gnG-8MA7PZNptJs5k02XYOzGY75706NljbCbuHrKPeDLw-AjY5O_Yxv9-nB07lD9HAM_f2wA3-Zrj1EY27NxUxoY1uuJ9DG7nV_Ac3Epfj</recordid><startdate>20040915</startdate><enddate>20040915</enddate><creator>HOLDENRIEDER, Stefan</creator><creator>STIEBER, Petra</creator><creator>VON PAWEL, Joachim</creator><creator>RAITH, Hannelore</creator><creator>NAGEL, Dorothea</creator><creator>FELDMANN, Knut</creator><creator>SEIDEL, Dietrich</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040915</creationdate><title>Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer</title><author>HOLDENRIEDER, Stefan ; STIEBER, Petra ; VON PAWEL, Joachim ; RAITH, Hannelore ; NAGEL, Dorothea ; FELDMANN, Knut ; SEIDEL, Dietrich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Neoplasm - blood</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Carcinoembryonic Antigen - biosynthesis</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Drug Resistance, Neoplasm</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Humans</topic><topic>Keratin-19</topic><topic>Keratins - metabolism</topic><topic>Kinetics</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Nucleosomes - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOLDENRIEDER, Stefan</creatorcontrib><creatorcontrib>STIEBER, Petra</creatorcontrib><creatorcontrib>VON PAWEL, Joachim</creatorcontrib><creatorcontrib>RAITH, Hannelore</creatorcontrib><creatorcontrib>NAGEL, Dorothea</creatorcontrib><creatorcontrib>FELDMANN, Knut</creatorcontrib><creatorcontrib>SEIDEL, Dietrich</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOLDENRIEDER, Stefan</au><au>STIEBER, Petra</au><au>VON PAWEL, Joachim</au><au>RAITH, Hannelore</au><au>NAGEL, Dorothea</au><au>FELDMANN, Knut</au><au>SEIDEL, Dietrich</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2004-09-15</date><risdate>2004</risdate><volume>10</volume><issue>18</issue><spage>5981</spage><epage>5987</epage><pages>5981-5987</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: We investigated the potential of circulating, nucleosomal DNA for the early prediction of the efficacy of chemotherapy in
patients with advanced lung cancer.
Experimental Design: In serum of 212 patients with newly diagnosed non–small cell lung cancer (stages III and IV) undergoing chemotherapy, nucleosomes
(ELISA, Roche) were measured at days 1, 3, 5, and 8 of the first cycle and before each new therapeutic cycle. Additionally,
carcinoembryonic antigen and cytokeratin 19 fragments (CYFRA 21–1; Elecsys, Roche) were determined before each cycle. The
therapeutic success was classified by computed tomography before start of the third cycle according to the World Health Organization
criteria.
Results: In univariate analysis, responders (patients with remission) showed significantly ( P < 0.05) lower values for the area under the curve of days 1 to 8 (AUC 1–8) of nucleosomes, the pretherapeutic baseline values
of cycle 2 (BV2) and cycle 3 (BV3) of nucleosomes, and higher decreases of the baseline values from cycle 1 to 2 (BV1–2) and
from cycle 1 to 3 (BV1–3) compared with nonresponders (patients with stable or progressive disease). Additionally, CYFRA 21–1
(BV1, BV2, BV3, BV1–2, BV1–3) and carcinoembryonic antigen (BV1–2) discriminated significantly between both groups.
In multivariate analysis including all parameters available until end of the first therapeutic cycle, nucleosomes (AUC 1–8),
CYFRA 21–1 (BV1), stage, and age were independent predictors of therapy response with nucleosomes (AUC 1–8) having the strongest
impact.
Conclusion: Circulating nucleosomes in combination with oncological biomarkers are valuable for the early estimation of the efficacy
of chemotherapy in patients with lung cancer.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15447981</pmid><doi>10.1158/1078-0432.CCR-04-0625</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1078-0432 |
ispartof | Clinical cancer research, 2004-09, Vol.10 (18), p.5981-5987 |
issn | 1078-0432 1557-3265 |
language | eng |
recordid | cdi_proquest_miscellaneous_66911684 |
source | Freely Accessible Journals |
subjects | Adult Aged Aged, 80 and over Antigens, Neoplasm - blood Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Carcinoembryonic Antigen - biosynthesis Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Drug Resistance, Neoplasm Enzyme-Linked Immunosorbent Assay Female Humans Keratin-19 Keratins - metabolism Kinetics Lung Neoplasms - blood Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Multivariate Analysis Nucleosomes - metabolism Pharmacology. Drug treatments Time Factors Treatment Outcome Tumors |
title | Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A42%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20Nucleosomes%20Predict%20the%20Response%20to%20Chemotherapy%20in%20Patients%20with%20Advanced%20Non%E2%80%93Small%20Cell%20Lung%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=HOLDENRIEDER,%20Stefan&rft.date=2004-09-15&rft.volume=10&rft.issue=18&rft.spage=5981&rft.epage=5987&rft.pages=5981-5987&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-04-0625&rft_dat=%3Cproquest_cross%3E66911684%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-2f236f3b2705cdf5bed6744801634dbe005aed36e2079ea01f86b50f898c2aa03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66911684&rft_id=info:pmid/15447981&rfr_iscdi=true |